Literature DB >> 9296462

Insights into the pathophysiology of unstable coronary artery disease.

S D Kristensen1, H B Ravn, E Falk.   

Abstract

Coronary atherosclerosis without thrombosis is, in general, a benign disease. However, plaque disruption, or fissuring, with superimposed thrombosis, frequently complicates the course of coronary atherosclerosis. Small ruptures often remain clinically silent, whereas more extensive plaque rupture may cause the development of unstable angina, myocardial infarction, and sudden death. The risk of plaque disruption depends more on plaque type (composition) than on plaque size and stenosis severity. Major determinants of a plaque's vulnerability to rupture are: the size and consistency of the lipid-rich atheromatous core; the thickness of the fibrous cap covering the core; and ongoing inflammation and repair within the cap. Both plaque vulnerability (intrinsic disease) and rupture triggers (extrinsic forces) are important for plaque disruption. The former predisposes the plaque to rupture whereas the latter may precipitate it. The resultant thrombotic response, which is important for the clinical presentation and outcome, is portly determined by the reactivity of the circulating platelets and the balance between the fibrinolytic and coagulation systems. New ways of identification and treatment of the dangerous vulnerable plaques responsible for infarction and death, and optimization of antithrombotic treatment, are highly warranted in order to prevent and treat life-threatening coronary thrombosis.

Entities:  

Mesh:

Year:  1997        PMID: 9296462     DOI: 10.1016/s0002-9149(97)00482-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Targeting the vulnerable plaque: the evolving role of nuclear imaging.

Authors:  John R Davies; James F Rudd; Tim D Fryer; Peter L Weissberg
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

2.  Cell therapy for myocardial infarction.

Authors:  Yoo-Wook Kwon; Han-Mo Yang; Hyun-Jai Cho
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

Review 3.  Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.

Authors:  K L Goa; S Noble
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

4.  Molecular imaging of atherosclerotic plaques with technetium-99m-labelled antisense oligonucleotides.

Authors:  Guangming Qin; Yongxue Zhang; Wei Cao; Rui An; Zairong Gao; Guiling Li; Wendai Xu; Kaijun Zhang; Shuren Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-11-26       Impact factor: 9.236

5.  Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy).

Authors:  Paul A Gurbel; Brian Galbut; Kevin P Bliden; Raymond D Bahr; Matthew T Roe; Victor L Serebruany; W Brian Gibler; Robert H Christenson; E Magnus Ohman
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

Review 6.  [Cytomegalovirus and herpes simplex virus in pathogenesis and progression of native arteriosclerosis and recurrent stenosis after intervention].

Authors:  M Herzum; J R Schaefer; G Hufnagel; B Maisch
Journal:  Herz       Date:  1998-05       Impact factor: 1.443

Review 7.  Mouse models of atherosclerosis: explaining critical roles of lipid metabolism and inflammation.

Authors:  Rupak Mukhopadhyay
Journal:  J Appl Genet       Date:  2013-01-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.